used without further purification. Rink amide MBHA resin (loading: 0.79 mmol/g) was purchased from Merck Millipore (Kenilworth, NJ, USA). Polypropylene tubing (Libra tube ® ) was purchased from HiPep Laboratories (Kyoto, Japan).
Recombinant mouse caspase-1 was purchased from BioVision (Milpitas, CA, USA). Enzyme activity was as follows: Caspase-1: 1 U = 1 nmol h −1 using Ac-WEHD-pNA from Peptide Institute, Inc. as a substrate at 37°C. NMR spectra were recorded on a JEOL JNM-AL400 instrument (Tokyo, Japan) at 400 MHz for 1 H NMR and 100.4 MHz for 13 C NMR; on a Bruker Ascend TM 500 instrument (Billerica, MA, USA) at 500 MHz for 1 H NMR and 125 MHz for 13 C NMR using tetramethylsilane as an internal standard; and at 376 MHz for 19 F NMR using sodium trifluoroacetate as an internal standard. Electrospray ionization mass spectra (ESI-MS) were obtained using a Waters LCT-Premier XE. Magnetic resonance imaging (MRI) was performed on a Bruker BioSpec 117/11 system equipped with a 35mm inner diameter volume coil at a frequency of 500 MHz for 1 H and 471 MHz for 19 F measurements. Image acquisition and processing were conducted using ParaVision software (Bruker BioSpin) and ImageJ software (NIH, Bethesda, MD, USA). Transmission electron microscopy (TEM) images were acquired using a HITACHI H-7650 at 120 kV (Tokyo, Japan). Particle size distribution was measured using a tunable resistive pulse sensor on a qNano nanoparticle analyzer (Meiwafosis Co., Ltd., Tokyo, Japan). Analytical reverse-phase HPLC was performed on an InertSustain C18 column 4.6 × 250 mm (GL Science, Inc., Tokyo, Japan) using an HPLC system composed of a pump PU-2080 (JASCO, Oklahoma City, OK, USA) and a detector MD-2010 (JASCO) . Eluents A (0.1% TFA in CH 3 CN) and B (0.1% TFA in H 2 O) were used as mobile phases.
Inductively coupled plasma (ICP) emission spectra were obtained on a Shimadzu ICPS-8100 (Kyoto, Japan).
Synthesis

Preparation of the Gd 3+ complex-conjugated peptides WEHD 1-3
Gd 3+ complex-conjugated peptides were synthesized by Fmoc chemistry on Rink amide MBHA resin using 1-hydroxybenzotriazole and (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate. Fmoc-Trp(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-His(Trt)-OH, Fmoc-Glu(OtBu)-OH, 8-(Fmoc-amino)-3,6-dioxa-n-octanoic acid, and 1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA) monoamide were conjugated, using Fmoc chemistry. Peptides were cleaved from the resin with 5% triisopropylsilane in trifluoroacetic acid.
After the solvent was removed, the residue was washed with diethyl ether. Next, the residue was dissolved in H 2 O containing 0.1% formic acid and lyophilized to obtain crude peptides. GdCl 3 ·6H 2 O was then added to the crude peptide solution in 0.1 M HEPES buffer (pH 7.4). The reaction mixture was stirred at room temperature for 24 h and purified by HPLC to obtain the WEHD 1-3 peptides. 
MS (ESI
Preparation of FLAME-WEHD 1
FLAME-NHS was prepared as per previously reported methods. S1 FLAME-NHS nanoparticles (C PFCE = 10 mM, 1 mL) were dispersed in dry DMF (10 mL) in an argon atmosphere. Next, WEHD 1 (100 mg) and dry triethylamine (1 mL, 7 mmol) were added to the solution, and the mixture was stirred for 24 h at 40°C. The product was separated by centrifugation (14,000 × g, 4°C, 30 min), washed three times with dry DMF and H 2 O, and finally dispersed in H 2 O (1 mL).
Preparation of FLAME-WEHD 2 and 3
FLAME-WEHD 2 and 3 were prepared as per the method described above for FLAME-WEHD 1, except for that FLAME-NHS nanoparticles were dispersed in 10 mL of dry DMF, and 100 mg and 140 mg of WEHD 2 and 3 was mixed with 1 mL (7 mmol) of dry trimethylamine for FLAME-WEHD 2 and 3, respectively. 
Experimental Procedures
Caspase-1 enzyme assay with WEHD 1-3
Caspase-1 reactivity with WEHD 1-3 was examined by incubating WEHD 1-3 (600 µM) with caspase-1 (0.012 U/µL) in 50 mM HEPES (pH 7.2) containing 50 mM NaCl, 10 mM DTT, 10 mM EDTA, 0.1% CHAPS, and 5% glycerol. After incubation at 37°C, caspase-1 was inactivated by heat shock. For HPLC analysis, the peptides were diluted with H 2 O (C peptide = 100 µM), and benzoic acid (500 µM) was added as an internal standard. Caspase-1 enzyme assay with FLAME-WEHD 1-3
Caspase-1 reactivity with FLAME-WEHD 1-3 was examined by incubating FLAME-WEHD 1-3 (C PFCE = 6.4 mM) with caspase-1 (0.12 U/µL) in 50 mM HEPES (pH 7.4) containing 50 mM NaCl, 10 mM DTT, 10 mM EDTA, 0.1% CHAPS, and 5% glycerol. After incubation at 37°C, the mixture was centrifuged (14,000 × g, 4°C, 30 min), and the supernatant was analyzed under HPLC.
Analytical conditions: a linear gradient of 0-40% acetonitrile containing 0.1% trifluoroacetic acid for 40 min, an InertSustain C18 column (4.6 × 250 mm), and a flow rate of 1.0 mL/min.
MRI measurement of FLAME-WEHD 1-3 with caspase-1
Caspase-1 enzyme assay was conducted by incubating FLAME-WEHD 1-3 (C PFCE = 6.4 mM) with caspase-1 (0.12 U/µL) in 50 mM HEPES (pH 7.4) containing 50 mM NaCl, 10 mM DTT, 10 mM EDTA, 0.1% CHAPS, and 5% glycerol. After incubation at 37°C for the indicated times, the mixture was heated at 95°C for 5 min, centrifuged (14,000 × g, 4°C, 30 min), and diluted with H 2 O (C PFCE = 2.0 mM). 19 F MRI RARE method: the image matrix was 128 × 64, field of view was 8 × 4 cm, and slice thickness was 40 mm. T R was 1000 ms. T E,eff was 6 ms. The number of averages was 512. The acquisition time was 2 h 16 min 32 s.
Mouse experimental procedure using FLAME-WEHD 3 and FLAME-COOH
All animal experimentation and handling was approved by the local ethics review board and was performed in accordance with the guidelines of the Animal Care and Use Committee of Osaka University. C57BL/6Jjcl mice were obtained from CLEA Japan (Tokyo, Japan), anesthetized with sevoflurane, and subjected to MRI for data acquisition. 1 H/ 19 F MRI images were acquired at 15 min, 3 h, and 6 h after subcutaneous injection of FLAME-COOH and FLAME-WEHD 3 (C PFCE = 1.67 mM, 120 µL), (Fig. 3) . Acquired images were converted to DICOM format and rendered in red hot color using ImageJ software (NIH, Bethesda, MD, USA 
ICP-AES measurement
Samples were digested by boiling in concentrated nitric acid for 1 h. Then, the concentration of Gd 3+ was measured using ICP-AES at 342.247 nm.
NMR measurements
NMR spectra were obtained on an Ascend TM 500 instrument (Bruker, Billerica, MA, USA) at 376
MHz. The 19 F NMR spectra of FLAMEs were referenced to sodium trifluoroacetate as an internal standard. FLAMEs were prepared in water containing 10% D 2 O. The T 2 relaxation times were measured using the spin-echo method.
qNano measurement qNano measurements were performed according to the IZON protocols. Nanoparticles were diluted in standard buffer (10 mM Tris-HCl, 100 mM KCl, 3 mM EDTA, and 0.03% Triton X-100, pH 7.4).
Nanoparticles were analyzed on an NP100 nanopore at a stretch of 47 mm with an applied voltage of 0.64 V. 7 Fig. S1 . Probe design of FLAME-WEHD 1-3. Table S1 . Hydrodynamic diameter of FLAME-WEHD 1-3 as measured by qNano. Data are presented as mean ± SD (n > 500).
Supporting Figures and Tables
Materials
Hydrodynamic diameter (nm) FLAME-WEHD 1 101 ± 17 FLAME-WEHD 2 127 ± 31 FLAME-WEHD 3 117 ± 18 43   Table S3 . Properties of FLAME-COOH and FLAME-WEHD 1-3.
Materials n 19F [a] n Gd [a] n 19F / n Gd [a] T 2 / ms FLAME-COOH 1.3 × 10 8 0 -432 FLAME-WEHD 1 1.0 × 10 8 2.3 × 10 4 4.3 × 10 3 61 FLAME-WEHD 2 1.3 × 10 8 3.1 × 10 4 4.2 × 10 3 63 FLAME-WEHD 3 1.4 × 10 8 5.1 × 10 4 2.7 × 10 3 50
[a] Values calculated via 19 F NMR spectroscopy, ICP-AES, and particle concentration. n 19F : the number of 19 F atoms in one nanoparticle. n Gd : the number of Gd 3+ atoms in one nanoparticle. Table S4 . Properties of FLAME-DEVD 1 and 2.
Materials n 19F n Gd n 19F / n Gd T 2 / ms FLAME-DEVD 1 9.2 × 10 7 1.5 × 10 4 6.1 × 10 3 88 FLAME-DEVD 2 8.0 × 10 7 8.6 × 10 4 9.3 × 10 2 97
The data are reproduced: reference. S2 
